The traditional paradigm of drug discovery and development is notoriously characterized by protracted timelines, exorbitant costs, and alarmingly high failure rates. Bringing a single new drug to market can take over a decade and cost billions of dollars, with success probabilities often below 10% from preclinical stages to regulatory approval. This formidable challenge underscores the urgent imperative for transformative technologies capable of fundamentally reshaping the pharmaceutical R&D landscape. Artificial intelligence
